德展健康(000813) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects to achieve a net profit attributable to shareholders of 8 million yuan for the first half of 2024, a significant increase of 205.76% compared to a loss of 7.56 million yuan in the same period last year[2] - The net profit after deducting non-recurring gains and losses is projected to be 6.5 million yuan, representing a 173.57% increase from a loss of 8.83 million yuan in the previous year[2] - Basic earnings per share are expected to be 0.0037 yuan, compared to a loss of 0.0034 yuan per share in the same period last year[2] - The increase in net profit is attributed to a year-on-year growth in operating revenue and a reduction in inventory impairment losses[4] Financial Reporting - The financial data presented is preliminary and has not been audited by an accounting firm, with the final figures to be disclosed in the 2024 semi-annual report[3][5] - The company emphasizes the importance of timely information disclosure in accordance with relevant laws and regulations[5]